Ke­to in a pill? Jim Mel­lon de­buts an­ti-ag­ing joint ven­ture with the Buck ded­i­cat­ed to in­duc­ing ke­to­sis

Jim Mel­lon

Click on the im­age to see the full-sized ver­sion


Jim Mel­lon’s crew at Ju­ve­nes­cence has found its lat­est ven­ture idea in a pop­u­lar di­et mak­ing its rounds in biotech cir­cles.

Er­ic Verdin

Once again team­ing up with the Buck In­sti­tute for Re­search on Ag­ing, Ju­ve­nes­cence has launched BHB Ther­a­peu­tics to ex­plore pre­ven­ta­tive med­i­cines that have po­ten­tial to pro­tect against age-re­lat­ed dis­ease by in­duc­ing a state of ke­to­sis, where the body burns fat in­stead of carbs, spurring the pro­duc­tion of an­ti-in­flam­ma­to­ry ke­tone bod­ies.

In par­tic­u­lar, the biotech start­up will fo­cus on the ke­tone body be­ta-hy­drox­y­bu­tyrate, or — you guessed it — BHB. Er­ic Verdin, the Buck pres­i­dent and CEO whose re­search in­spired an­oth­er Ju­ve­nes­cence spin­out, has dis­cov­ered that BHB helps the body re­spond to stress.

John New­man

A ke­to­genic di­et — which has been her­ald­ed for its ef­fects in weight loss, hunger sup­pres­sion as well as con­cen­tra­tion — and the con­se­quent longterm ex­po­sure to ke­tone bod­ies can al­so ex­tend healthy lifes­pan in mod­el sys­tems, Verdin and col­lab­o­ra­tor John New­man found.

The duo has gen­er­at­ed “hard sci­en­tif­ic da­ta” in mice that show ke­to­sis can be car­dio-pro­tec­tive, CEO Greg Bai­ley told End­points News. Ob­vi­ous­ly, they have a long way to go.

“The rea­son we think that car­dio-pro­tec­tion may trans­late to hu­mans is be­cause if giv­en sug­ar or ke­tones, many peo­ple’s hearts pre­fer ke­tones, where­as the brain is the op­po­site,” he said. “If giv­en the op­tion be­tween sug­ar or ke­tones, the brain will take sug­ar. Un­for­tu­nate­ly, in­di­vid­u­als when they hit 50 (plus or mi­nus a cou­ple years) they be­come in­sulin re­sis­tant — and then the sug­ar can go se­ri­ous­ly high in a va­ri­ety of or­gans and that leads to a va­ri­ety of dif­fer­ent patholo­gies.”

The com­pa­ny is look­ing to be­gin “ag­gres­sive safe­ty stud­ies” in the near-term, Bai­ley added. Should the com­pounds be found safe, he plans to take al­ter­na­tive routes rather than the con­ven­tion­al reg­u­la­to­ry path­way — which he be­lieves can lead to quick­er hu­man test­ing.

Greg Bai­ley

Just days ago, Ju­ve­nes­cence un­veiled the first $46 mil­lion tranche of a promised $100 mil­lion raise that’s de­signed to bankroll longevi­ty projects with the col­lec­tive goal of ex­tend­ing the hu­man lifes­pan to 150 years. So far, it’s ticked off stem cell tech and or­gan re­gen­er­a­tion among the fields it’s es­tab­lished it­self through joint ven­tures with AI groups — In­sil­i­co and Ne­tra­mark — and con­trol­ling in­ter­ests in AgeX and Ly­Ge­n­e­sis.

The goal, founder and chair­man Mel­lon said back then, is to have 18 projects un­der­way by the end of the year.

Look for two or three of them to be an­nounced over the next few weeks, Bai­ley said, not­ing that there should al­so be three or four let­ters of in­tent go­ing out short­ly.


With ad­di­tion­al re­port­ing by Na­tal­ie Grover.

Im­ple­ment­ing re­silience in the clin­i­cal tri­al sup­ply chain

Since January 2020, the clinical trials ecosystem has quickly evolved to manage roadblocks impeding clinical trial integrity, and patient care and safety amid a global pandemic. Closed borders, reduced air traffic and delayed or canceled flights disrupted global distribution, revealing how flexible logistics and supply chains can secure the timely delivery of clinical drug products and therapies to sites and patients.

In fi­nal days at Mer­ck, Roger Perl­mut­ter bets big on a lit­tle-known Covid-19 treat­ment

Roger Perlmutter is spending his last days at Merck, well, spending.

Two weeks after snapping up the antibody-drug conjugate biotech VelosBio for $2.75 billion, Merck announced today that it had purchased OncoImmune and its experimental Covid-19 drug for $425 million. The drug, known as CD24Fc, appeared to reduce the risk of respiratory failure or death in severe Covid-19 patients by 50% in a 203-person Phase III trial, OncoImmune said in September.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 94,100+ biopharma pros reading Endpoints daily — and it's free.

Pascal Soriot (AP Images)

UP­DAT­ED: As­traZeneca, Ox­ford on the de­fen­sive as skep­tics dis­miss 70% av­er­age ef­fi­ca­cy for Covid-19 vac­cine

On the third straight Monday that the world wakes up to positive vaccine news, AstraZeneca and Oxford are declaring a new Phase III milestone in the fight against the pandemic. Not everyone is convinced they will play a big part, though.

With an average efficacy of 70%, the headline number struck analysts as less impressive than the 95% and 94.5% protection that Pfizer/BioNTech and Moderna have boasted in the past two weeks, respectively. But the British partners say they have several other bright spots going for their candidate. One of the two dosing regimens tested in Phase III showed a better profile, bringing efficacy up to 90%; the adenovirus vector-based vaccine requires minimal refrigeration, which may mean easier distribution; and AstraZeneca has pledged to sell it at a fraction of the price that the other two vaccine developers are charging.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 94,100+ biopharma pros reading Endpoints daily — and it's free.

Feng Tian, Ambrx CEO (Ambrx)

Af­ter 5 qui­et years, a for­mer Scripps spin­out rais­es $200M and an­nounces plans to try again at an IPO

The first time San Diego biotech Ambrx tried to go public in 2014, they failed and the company’s board switched to a radically different strategy: They sold themselves for an undisclosed amount to a syndicate of Chinese investors and pharma companies.

Now, after 5 quiet years, that syndicate has raised a mountain of cash and indicated they’ll soon make another bid to go public.

Earlier this month, Ambrx raised $200 million in what they billed as a crossover round financed by Fidelity, BlackRock, Cormorant Asset Management, HBM Healthcare Investments, Invus, Adage Capital Partners and Suvretta Capital Management. It’s the largest amount they’ve ever raised and, according to Crunchbase figures, more than doubles the total amount of VC capital collected since their launch 17 years ago.

The ad­u­canum­ab co­nun­drum: The PhI­II failed a clear reg­u­la­to­ry stan­dard, but no one is cer­tain what that means any­more at the FDA

Eighteen days ago, virtually all of the outside experts on an FDA adcomm got together to mug the agency’s Billy Dunn and the Biogen team when they presented their upbeat assessment on aducanumab. But here we are, more than 2 weeks later, and the ongoing debate over that Alzheimer’s drug’s fate continues unabated.

Instead of simply ruling out any chance of an approval, the logical conclusion based on what we heard during that session, a series of questionable approvals that preceded the controversy over the agency’s recent EUA decisions has come back to haunt the FDA, where the power of precedent is leaving an opening some experts believe can still be exploited by the big biotech.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Bob Nelsen (Photo by Michael Kovac/Getty Images)

Bob Nelsen rais­es $800M and re­cruits a star-stud­ded board to build the 'Fox­con­n' of biotech

Bob Nelsen spent his pandemic spring in his Seattle home, talking on the phone with Luciana Borio, the scientist who used to run pandemic preparedness on the National Security Council, and fuming with her about the dire state of American manufacturing.

Companies were rushing to develop vaccines and antibodies for the new virus, but even if they succeeded, there was no immediate supply chain or infrastructure to mass-produce them in a way that could make a dent in the outbreak.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 94,100+ biopharma pros reading Endpoints daily — and it's free.

John Maraganore, Alnylam CEO (Scott Eisen/Bloomberg via Getty Images)

UP­DAT­ED: Al­ny­lam gets the green light from the FDA for drug #3 — and CEO John Maraganore is ready to roll

Score another early win at the FDA for Alnylam.

The FDA put out word today that the agency has approved its third drug, lumasiran, for primary hyperoxaluria type 1, better known as PH1. The news comes just 4 days after the European Commission took the lead in offering a green light.

An ultra rare genetic condition, Alnylam CEO John Maraganore says there are only some 1,000 to 1,700 patients in the US and Europe at any particular point. The patients, mostly kids, suffer from an overproduction of oxalate in the liver that spurs the development of kidney stones, right through to end stage kidney disease.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 94,100+ biopharma pros reading Endpoints daily — and it's free.

Pur­due Phar­ma pleads guilty in fed­er­al Oxy­Con­tin probe, for­mal­ly rec­og­niz­ing it played a part in the opi­oid cri­sis

Purdue Pharma, the producer of the prescription painkiller OxyContin, admitted Tuesday that, yes, it did contribute to America’s opioid epidemic.

The drugmaker formally pleaded guilty to three criminal charges, the AP reported, including getting in the way of the DEA’s efforts to combat the crisis, failing to prevent the painkillers from ending up on the black market and encouraging doctors to write more painkiller prescriptions through two methods: paying them in a speakers program and directing a medical records company to send them certain patient information. Purdue’s plea deal calls for $8.3 billion in criminal fines and penalties, but the company is only liable for a fraction of that total — $225 million.

News brief­ing: Gilead part­ner Gala­pa­gos sells off CRO for $37M; Polyphor bags $3.3M from CF Foun­da­tion

Close Gilead ally Galapagos is selling off one of its contract research organizations to a Polish pharma company.

Galapagos has agreed to sell 100% of the outstanding shares in the CRO Fidelta to Selvita, in a deal worth roughly $37 million expected to close in the first week of January. The acquisition is expected to nearly double Selvita’s revenues, the company says, as well as expand its drug discovery efforts.